Momenta Phama (MNTA) Misses Q3 EPS by 8c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Burry doubles down on Nebius short after stock surges 34% on earnings
- Total darkness, then sunset as full eclipse wows spectators in Spain
AbbVie (ABBV) Announces HUMIRA Global Patent License with Momenta (MNTA)
November 6, 2018 5:05 PM ESTAbbVie (NYSE: ABBV) announced today patent license agreements with Momenta (Nasdaq: MNTA) over its proposed biosimilar adalimumab product. Under the terms of the agreements, AbbVie will grant Momenta a non-exclusive license on specified dates to AbbVie's intellectual... More
Piper Jaffray Starts Momenta Pharmaceuticals (MNTA) at Overweight
November 5, 2018 5:03 AM ESTPiper Jaffray analyst Danielle Brill initiates coverage on Momenta Pharmaceuticals (NASDAQ: MNTA) with a Overweight rating and a price target of $35.00.
For an analyst ratings summary and ratings history on Momenta Pharmaceuticals click here. For more ratings news on Momenta Pharmaceuticals click here.
Shares of Momenta Pharmaceuticals closed at $13.66 yesterday.
... More